RxDoctor Payments DataLook up a doctor →

Tammy Torrey

Medical · Largo, FLNPI 1033203724

Payments from drug & device makers

$14,816in general payments, 2019–2025

Across 718 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Gilead$952
  • QOL Medical, LLC$937
  • plus $6K from 28 others

What the payments were for

  • Food & beverage$14,53798%
  • Education$2792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,816 in reported general payments places this provider in the 95th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$42,432
Medicare patients
271
Services billed
397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase15$108,881
XifaxanRifaximin17$53,113
LinzessLinaclotide16$22,685
TrulancePlecanatide16$10,658
Ursodiol15$6,093
Pantoprazole Sodium239$3,087
Omeprazole87$1,640
Esomeprazole Magnesium55$1,586
Famotidine63$1,119
Dicyclomine Hcl22$1,010
Colestipol Hcl14$809
Lactulose40$518
Ondansetron OdtOndansetron33$508
Metronidazole23$126
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$3,091$131,56631 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,077$63,77033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,031 medical providers in Florida.

Other medical in Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →